Feb 28, 2019 5:00 pm EST Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
Jan 14, 2019 2:15 pm EST UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
Jan 14, 2019 8:00 am EST Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
Jan 08, 2019 7:30 am EST Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Nov 26, 2018 7:00 am EST Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum